{"name":"Larimar Therapeutics","slug":"larimar","ticker":"LRMR","exchange":"NASDAQ","domain":"larimartx.com","description":"Larimar Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases and neurological disorders. The company's pipeline includes several promising candidates, including its lead product, LMI070. Larimar Therapeutics is a relatively small player in the rare disease/neurology space, but its innovative approach and strong management team have generated significant interest among investors.","hq":"Bala Cynwyd, PA","founded":0,"employees":"","ceo":"Carole Ben-Maimon","sector":"Rare Disease / Neurology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$420M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":154224000,"netIncome":-165673000,"cash":85412000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2019"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"LMI070 patent cliff ($0.0B at risk)","drug":"LMI070","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CTI-1601","genericName":"CTI-1601","slug":"cti-1601","indication":"Amyotrophic lateral sclerosis (ALS)","status":"phase_2"}]}],"pipeline":[{"name":"CTI-1601","genericName":"CTI-1601","slug":"cti-1601","phase":"phase_2","mechanism":"CTI-1601 is a gene therapy that aims to restore motor neuron function in patients with amyotrophic lateral sclerosis (ALS).","indications":["Amyotrophic lateral sclerosis (ALS)"],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Larimar Therapeutics Announces FDA Clearance of IND for LMI070","summary":"Larimar Therapeutics announced that the FDA has cleared the Investigational New Drug (IND) application for LMI070, enabling the company to initiate a Phase 1/2 clinical trial.","drugName":"LMI070","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Larimar Therapeutics Reports Third Quarter 2023 Financial Results","summary":"Larimar Therapeutics reported its third quarter 2023 financial results, with a net loss of $13.4 million and a cash balance of $123.6 million.","drugName":"","sentiment":"neutral"}],"realNews":[{"date":"2026-03-19","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNSVVnNVFsaXh6blpvbEIzbTZyQnlpSG41TTAyaXd1SllRdEF4ZGUxSC1PVU80STVGRjJrOXBBcXdTSXU0TU1pSzZsNnZJNmctNmstTG55RlVVbnBORmt3bVRzdkFUT21SbGxuUzZoYzBkX1lVTl9IMmdCdmlZWDdHOEU2M2JhRnlka3JaaFBDaVZjZ0VWbUp0ZVd0NlluZXc0WVlXMlU1U053LU1pS1RyVVRJRExUbkVabkRHVnB3?oc=5","date":"2026-03-06","type":"pipeline","source":"TradingView","summary":"LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month? - TradingView","headline":"LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-27","type":"pipeline","source":"simplywall.st","summary":"Larimar Therapeutics (LRMR) Is Up 85.9% After Breakthrough Status For Nomlabofusp In Friedreich’s Ataxia - simplywall.st","headline":"Larimar Therapeutics (LRMR) Is Up 85.9% After Breakthrough Status For Nomlabofusp In Friedreich’s Ataxia","sentiment":"neutral"},{"date":"2026-02-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxNSG5BVTBQem1KdDYyYm40SDB1MGNhRTMxaXVQSVlhMDVkcHZLOXhHY3VEV21ab1ZhWkV0Tmg0NzAzaFM4ckx5aDRzRVhVOVV1c2JCN1BKZDZPWnFXaHhGNHFGYmI1NGxJQTJRM3doRkVsNFQ5am5GdnpKcEd5cXZyUll2WWRLRVJDTWNqcWZadzloN2NxWTNrVlFFOVVxcXotNmpGYklJQ0FJNVBQYXdDUmc3U1RyWHVDMEN3OW1EUkNmRHN5b3FpeXNjMEFMWGJZSTllRlBQSVZOTVNSNnExMm5OYUcwUzFhS1HSAe8BQVVfeXFMTVIzMVhST0lHNzYxSEtpV19CV3A5UDVJWl9ldGJvZWZMU3F1YVJoY2ZMWW4zWUJ6eW9YZjlQYXA0bXJybTBWeHRxa2FOaFBjVVlGdDFOVUFJVTh0MjNZQi1aQUJQQ3BGMWpicVRfY3VadnpqNzl6QkZBVEtRN3ZsMUNneGtTbmx1cnU4N0hUbUVveC1hWXNmQTc4Uy1pZ1VSWXY2ZWlHZVVYR0lfZXBLbjNRVnp2TGQ1azk1emgyVm1wQnBON3ZLSEwtOTJpMEpMdnpVOFh6VFFWQTFFUXF6NEhWSFh4RHBac1laUzRkX0k?oc=5","date":"2026-02-25","type":"regulatory","source":"simplywall.st","summary":"Larimar Therapeutics (LRMR) Valuation After FDA Breakthrough Therapy Designation For Nomlabofusp - simplywall.st","headline":"Larimar Therapeutics (LRMR) Valuation After FDA Breakthrough Therapy Designation For Nomlabofusp","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQQmU4N2hWTlEwb1lUSHJfeXlnOFlDbkRyWUNyZWxPT29QX3Z0NUl0eTE4UGJTZGEtM3U5dEhYeGNNRFVwMHROZm1CdzhVenJlRDA1OFNnTHozaThIWVZ1ejlsQzdLOUhHSXpiT2VCR1FDM2d0VDZLd0c3WjZRcDM0RGgwVGhkNWczem9Fb2F4N1Z6bmh3Tjc3a1Qtd1A5MEk3R21YMWxocmdLR2FSdEpRelZpRzEyREhTNUNTVVpR?oc=5","date":"2026-02-24","type":"pipeline","source":"Stocktwits","summary":"Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? - Stocktwits","headline":"Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today?","sentiment":"neutral"},{"date":"2026-02-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-22","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNdy1lSGJ2RlhKVTF0VThDVGtLX2c5WERFVUItWGJSQ0VBRE0yaTJ6WjMyMWRnRTlYenItRk5YWm5hWnVXTlVoRlFWTk9weEZzcVlLVXAtbjBWYVFwSGg3NEN1SnBodFU0Yzh4SHMySl9YTWlxam8tZkpDU0gtYnlhdkJkVE1WbFRa?oc=5","date":"2025-10-02","type":"regulatory","source":"Mugglehead Magazine","summary":"Larimar Therapeutics shares jump on positive FDA guidance - Mugglehead Magazine","headline":"Larimar Therapeutics shares jump on positive FDA guidance","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-23","type":"pipeline","source":"simplywall.st","summary":"Following a 31% decline over last year, recent gains may please Larimar Therapeutics, Inc. (NASDAQ:LRMR) hedge funds owners - simplywall.st","headline":"Following a 31% decline over last year, recent gains may please Larimar Therapeutics, Inc. (NASDAQ:LRMR) hedge funds own","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxPX1FtZG1rLWRQd20tOXZfUDdCUWVyeWoyWFd6c1VlUklEZjBzUDhkRUtaSzUyemtHUjRQU1FvempFcVFJZ3dzeU43VnA0dW5VSlpSVlhqeV9FYXRqZk9GUDZkOTBqcmlWN3RHQWplNTloM2s2MEJ1TENOSlR1UldiSktxWmo5UDEwdlpLQWxOT0xyX2pXWFh0bFhjWDl4dGJhanEzM1d0NnZXbkVaLUhIaERKbmw4ZmN4NDltc0FQbm5Ob1k1Mk11cmNUNXQteWhISElpdkU5TE55ZGs?oc=5","date":"2025-07-16","type":"deal","source":"The Globe and Mail","summary":"5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats - The Globe and Mail","headline":"5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE5uNXMwU05tVDdSNnQzSnJGUXZmSjNvZXVGNWJCUUxJbFlVVWszN0pVQXZxMm9FZ0Z1dS12SFpmeEpUOE9CTFk2c1EyRzdQSmp4Z2poN0pCdHdXM2l0RUJGQ1JVS3lhT2gw?oc=5","date":"2025-07-09","type":"regulatory","source":"MarketBeat","summary":"Larimar Therapeutics (LRMR) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $LRMR - MarketBeat","headline":"Larimar Therapeutics (LRMR) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $LRMR","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE4ySHE0TUdCYVVzVWMwVzhhb2lONm9Eb0kxV25UazVuT210X3lod2FtUmRzSXlNTkRvRmpXYlNZOGRHSUhXX21lbVkwVUV6R1ZlYnBZ?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"LRMR Stock Price, News & Analysis - Stock Titan","headline":"LRMR Stock Price, News & Analysis","sentiment":"neutral"}],"patents":[{"drugName":"LMI070","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Biohaven Pharmaceuticals","Sage Therapeutics","Cerevel Therapeutics"],"therapeuticFocus":["Rare Diseases","Neurology"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2019-12-31","revenueHistory":[{"value":0,"period":"2019-12-31"},{"value":0,"period":"2019-09-30"},{"value":0,"period":"2019-06-30"},{"value":0,"period":"2019-03-31"},{"value":0,"period":"2018-12-31"},{"value":0,"period":"2018-09-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":154224000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-165673000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":85412000,"cashHistory":[],"totalAssets":145842000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}